This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Apollo Endosurgery 配当金

配当金基準チェック /06

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	1.7%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.69
配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

Assessing Apollo Endosurgery

Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Apollo Endosurgery EPS beats by $0.10, beats on revenue

Nov 05

決済の安定と成長

配当データの取得

安定した配当: Insufficient data to determine if APEN's dividends per share have been stable in the past.

増加する配当: Insufficient data to determine if APEN's dividend payments have been increasing.

配当利回り対市場

Apollo Endosurgery 配当利回り対市場

APEN 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (APEN)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Medical Equipment)	1.7%
アナリスト予想 (APEN) (最長3年)	n/a

注目すべき配当: Unable to evaluate APEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

高配当: Unable to evaluate APEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

株主への利益配当

収益カバレッジ: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

株主配当金

キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as APEN has not reported any payouts.

This company has been acquired

Apollo Endosurgery 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Price target decreased to US$11.75

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Apollo Endosurgery, Inc. Announces Board Changes

Price target decreased to US$12.67

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

Apollo Endosurgery EPS beats by $0.05, beats on revenue

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Assessing Apollo Endosurgery

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

Apollo Endosurgery EPS beats by $0.10, beats on revenue

New 90-day high: US$1.79

New 90-day low - US$1.31

First half earnings released

Apollo Endosurgery, Inc. announced that it expects to receive $25 million in funding

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06